CrystalGenomics, Inc. (083790.KQ)

KRW 2545.0

(0.99%)

Long Term Debt Summary of CrystalGenomics, Inc.

CrystalGenomics, Inc.'s latest annual long term debt in 2023 was 29.88 Billion USD , up 45.74% from previous year.
CrystalGenomics, Inc.'s latest quarterly long term debt in 2024 Q1 was 28.92 Billion KRW , down -3.3% from previous quarter.
CrystalGenomics, Inc. reported annual long term debt of 20.5 Billion USD in 2022, down -15.95% from previous year.
CrystalGenomics, Inc. reported annual long term debt of 24.39 Billion USD in 2021, up 65.27% from previous year.
CrystalGenomics, Inc. reported quarterly long term debt of 24.91 Billion KRW for 2024 Q2, up 19.48% from previous quarter.
CrystalGenomics, Inc. reported quarterly long term debt of 29.88 Billion USD for 2023 FY, up 45.74% from previous quarter.

Annual Long Term Debt Chart of CrystalGenomics, Inc. (2023 - 2013)

Historical Annual Long Term Debt of CrystalGenomics, Inc. (2023 - 2013)

Year	Long Term Debt	Long Term Debt Growth
2023	29.88 Billion USD	45.74%
2022	20.5 Billion USD	-15.95%
2021	24.39 Billion USD	65.27%
2020	14.76 Billion USD	176.98%
2019	5.33 Billion USD	6.47%
2018	5 Billion USD	-1.48%
2017	5.08 Billion USD	3.19%
2016	4.92 Billion USD	6.47%
2015	4.62 Billion USD	11.65%
2014	4.14 Billion USD	3.21%
2013	4.01 Billion USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	28.92 Billion KRW	-3.3%
2024 Q2	24.91 Billion KRW	19.48%
2023 FY	29.88 Billion USD	45.74%
2023 Q1	29.14 Billion USD	42.13%
2023 Q3	32.26 Billion USD	-4.87%
2023 Q2	33.91 Billion KRW	16.37%
2023 Q4	29.88 Billion USD	-7.37%
2022 FY	20.5 Billion USD	-15.95%
2022 Q3	9.17 Billion USD	0.0%
2022 Q1	8.71 Billion USD	49.24%
2022 Q4	20.5 Billion USD	123.46%
2021 Q4	5.84 Billion USD	10.84%
2021 FY	24.39 Billion USD	65.27%
2021 Q1	5.26 Billion USD	-4.48%
2021 Q3	5.26 Billion USD	0.0%
2020 Q1	5.41 Billion USD	2.48%
2020 Q4	5.51 Billion USD	0.03%
2020 FY	14.76 Billion USD	176.98%
2020 Q3	5.51 Billion USD	0.0%
2019 FY	5.33 Billion USD	6.47%
2019 Q4	5.28 Billion USD	1.56%
2019 Q1	5.15 Billion USD	0.8%
2019 Q3	5.2 Billion USD	0.0%
2018 Q1	4.95 Billion USD	-1.76%
2018 FY	5 Billion USD	-1.48%
2018 Q4	5.11 Billion USD	2.1%
2018 Q3	5 Billion USD	0.0%
2017 Q1	5.15 Billion USD	0.02%
2017 Q4	5.04 Billion USD	-0.74%
2017 Q3	5.08 Billion USD	0.0%
2017 FY	5.08 Billion USD	3.19%
2016 Q1	4.95 Billion USD	12.9%
2016 Q3	4.92 Billion USD	0.0%
2016 Q4	5.15 Billion USD	4.63%
2016 FY	4.92 Billion USD	6.47%
2015 Q1	4.53 Billion USD	17.36%
2015 FY	4.62 Billion USD	11.65%
2015 Q4	4.38 Billion USD	-5.13%
2015 Q3	4.62 Billion USD	0.0%
2014 Q1	4.16 Billion USD	3.74%
2014 FY	4.14 Billion USD	3.21%
2014 Q4	3.86 Billion USD	-6.74%
2014 Q3	4.14 Billion USD	0.0%
2013 Q4	4.01 Billion USD	-0.0%
2013 Q3	4.01 Billion USD	0.0%
2013 FY	4.01 Billion USD	0.0%
2013 Q1	4 Billion USD	13.89%
2012 Q4	3.51 Billion USD	0.0%

Peer Long Term Debt Comparison of CrystalGenomics, Inc.

Name	Long Term Debt	Long Term Debt Difference
HLB Co., Ltd.	17.93 Billion KRW	-66.67%
iNtRON Biotechnology, Inc.	258.29 Million KRW	-11471.766%
BINEX Co., Ltd.	5.57 Billion KRW	-435.808%
Bioneer Corporation	12.5 Billion KRW	-139.114%
Anterogen.Co.,Ltd.	- KRW	-Infinity%
MEDIPOST Co., Ltd.	6.99 Billion KRW	-327.3%
Helixmith Co., Ltd	151.68 Million KRW	-19605.483%
Chabiotech Co.,Ltd.	95.06 Billion KRW	68.56%
Medy-Tox Inc.	1.22 Billion KRW	-2338.265%
Peptron, Inc.	4.5 Billion KRW	-564.206%
Amicogen, Inc.	70.65 Billion KRW	57.696%
Genexine, Inc.	22.68 Billion KRW	-31.779%
HLB Therapeutics Co.,Ltd.	1.84 Billion KRW	-1524.249%
LegoChem Biosciences, Inc.	528.37 Million KRW	-5556.855%
ALTEOGEN Inc.	1.24 Billion KRW	-2292.564%
PharmaResearch Co., Ltd.	970.71 Million KRW	-2979.092%
SillaJen, Inc.	8.13 Billion KRW	-267.377%
JETEMA, Co., Ltd.	60 Billion KRW	50.185%
OliX Pharmaceuticals,Inc	35.36 Billion KRW	15.475%
Genomictree Inc.	97.51 Million KRW	-30550.745%
MedPacto, Inc.	1.68 Billion KRW	-1671.798%
D&D Pharmatech	5.12 Billion KRW	-483.704%
EASY BIO,Inc.	30 Billion KRW	0.369%
GI Innovation, Inc.	2.9 Billion KRW	-929.243%